Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR.
We present here the first data available on resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) in India. In these subtype C isolates, we have observed most of the mutations noted in reverse transcriptase (RT) for subtype B with some additional substitutions (at positions 98, 203, 208, and 221) that will warrant attention in the algorithms used.
Deshpande
Alaka
A
Grant Medical College and Sir JJ Hospital, Byculla, Mumbai, India.
Jauvin
Valérie
V
Magnin
Noel
N
Pinson
Patricia
P
Faure
Muriel
M
Masquelier
Bernard
B
Aurillac-Lavignolle
Valérie
V
Fleury
Hervé J
HJ
D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D007194:India; D009154:Mutation / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics; D012194:RNA-Directed DNA Polymerase / Q000235:genetics*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D017211:Treatment Failure
D018894:Reverse Transcriptase Inhibitors; D012194:RNA-Directed DNA Polymerase